Micofenolato Mofetile Ahcl

Mycophenolate Mofetil, the active ingredient in Micofenolato Ahcl, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. It is employed to prevent organ transplant rejection and to treat lupus nephritis in appropriate patient populations.

GNH USA supplies Micofenolato Ahcl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil works within the immunosuppressive drug class to inhibit lymphocyte proliferation, making it useful for several transplant‑related and autoimmune conditions. - Kidney transplant rejection: helps prevent graft loss by suppressing immune response. - Heart transplant rejection: reduces the risk of acute rejection episodes. - Liver transplant rejection: supports long‑term graft survival. - Lupus nephritis: diminishes renal inflammation and proteinuria in systemic lupus erythematosus.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: increased bowel movements, sometimes watery. - Headache: transient cranial discomfort. - Abdominal pain: cramping or discomfort in the stomach area.

Serious or Rare Side Effects: - Severe infection: heightened risk of bacterial, viral, or fungal infections. - Bone marrow suppression: anemia, leukopenia, or thrombocytopenia. - Hepatotoxicity: elevated liver enzymes or liver injury. - Malignancy risk: potential increased incidence of certain cancers.

Patients receiving Mycophenolate Mofetil should be monitored regularly for safety and efficacy. - Blood counts: monitor for anemia, leukopenia, and thrombocytopenia. - Liver function: assess hepatic enzymes periodically. - Renal function: evaluate creatinine and glomerular filtration rate. - Hypersensitivity: discontinue if rash, pruritus, or anaphylaxis occurs. - Contraception: use effective birth control during treatment and for a defined period after discontinuation. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mycophenolate Mofetil may interact with several medicines, requiring careful management. Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression increases risk of cytopenias. - Live vaccines: heightened risk of infection due to immunosuppression. - Cholestyramine: reduces mycophenolate absorption, lowering efficacy. Moderate Interactions (Monitor Closely): - Antacids (aluminum or magnesium): may decrease drug absorption; separate dosing times. - Cyclosporine or tacrolimus: may increase mycophenolate exposure, requiring dose adjustment. - Warfarin: potential alteration of anticoagulant effect; monitor INR closely.